Author

Phylicia Wisti

Moderna Therapeutics (United States)

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:mouse· 1

Frequent Co-Authors

Adrian R. LaciakiD· 1 shared Alec W. FreyniD· 1 shared Amy Gorrie· 1 shared Andrea Carfı́iD· 1 shared Arshan NasiriD· 1 shared Arvind SharmaiD· 1 shared Cathal HarmoniD· 1 shared Clinton O. OgegaiD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

Adrian R. LaciakORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

mRNA-1273.251 and mRNA-1283.251 vaccines expressing SARS-CoV-2 variant LP.8.1 antigens broadly neutralize contemporary JN.1-lineage viruses

Arshan Nasir, Diana Wing Lee, Ziqiu Wang, Clinton O. Ogega, Nathen E. Bopp, Phylicia Wisti, Daniel L. Makrinos, Hardik Jani, Amy Gorrie, Michael F. Bender, Adrian R. Laciak, Arvind Sharma, Xiaozhen Hu, Tessa Speidel, Fadi Ghantous, , Alec W. Freyn

This study develops and evaluates two mRNA vaccines targeting the LP.8.1 variant of SARS-CoV-2, showing broad neutralization against JN.1-lineage subvariants.

bioRxiv · Sep 16, 2025 · PreprintImmunology